The era of standardization, precision and immunotherapy for locally advanced gastric cancer

Locally advanced gastric cancer accounts for 70% of clinically confirmed cases in China. Standard lymph node dissection is essential to ensure the quality of operation, and the rational lymph node dissection for adenocarcinoma of gastroesophageal junction still needs to be further explored. Radical gastrectomy with preservation of greater omentum still needs clinical evidence. Indocyanine green lymphatic navigation is a sign of accurate lymph node dissection. Peri⁃operative chemotherapy with SOX regimen (oxaliplatin and S-1) is the standard treatment for locally advanced gastric cancer in China. Perioperative immune‑chemotherapy is being actively explored. In the era of immunotherapy, the conversion therapy of stage Ⅳ gastric cancer is expected to make new breakthrough.